Leerink analyst Ana Gupte views the recent pullback in Cigna shares as a buying opportunity following the company's "solid" Q4 results. News of the Amazon, JPMorgan, Berkshire healthcare coalition, while an overhang, is more headline risk than anything else, Gupte tells investors in a research note. She believes Cigna is likely to build on its "industry-leading" medical cost trend for employers, with a focus on improving the out-of-pocket cost, experience and transparency for the U.S. worker. The analyst reiterates an Outperform rating on the shares with a $250 price target.